<span style="color: #222222;">The Drugs Controller General of India (DCGI) has approved trial of a drug for reducing mortality rate in critically ill COVID-19 patients. The trial is likely to begin at multiple hospitals. The drug which has been developed by Cadila Pharmaceuticals Ltd. with the support of Council of Scientific and Industrial Research (CSIR) is meant to treat critically ill patients suffering from Gram-negative bacterial sepsis. CSIR appointed monitoring committee supervised the research trials and development of this drug which has proved it's efficacy in providing faster recovery from organ dysfunction seen in infected patients.<br />'' <br />'' Looking at similarities between clinical characteristics of patients suffering from COVID-19 and Gram-negative sepsis, CSIR, is now initiating a randomized, active comparator-controlled clinical trial to evaluate the efficacy of this drug for critically ill COVID-19 patients.<br />'' <br />''<br />''The drug has been found to be extremely safe in patients and no systemic side effects are associated with its use. It can be used concurrently with any other therapeutic treatments.</span><br />